Evidence map›Paper›PMID 39612757›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2025

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.

C Robert, G V Long, J Larkin, J D Wolchok, J C Hassel, D Schadendorf, F S Hodi, C Lebbé, J-J Grob, J R Hyngstrom and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

C RobertGustave Roussy and Paris-Saclay University, Villejuif-Paris Sud, France. Electronic address: caroline.robert@gustaveroussy.fr.
G V LongMelanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
J LarkinRoyal Marsden NHS Foundation Trust, London, United Kingdom.
J D WolchokMeyer Cancer Center, Weill Cornell Medical College, New York, NY, USA.
J C HasselHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.
D SchadendorfUniversity Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, Germany & National Center for Tumor Diseases (NCT)-West, Campus Essen, & Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
F S HodiDana-Farber Cancer Institute, Boston, MA, USA.
C LebbéUniversité Paris Cité, AP-HP Dermatolo-oncology, Cancer Institute APHP.nord Paris-cité, INSERM U976, Saint-Louis Hospital, Paris, France.
J-J GrobAix-Marseille University, APHM Timone, Marseille, France.
J R HyngstromHuntsman Cancer Institute, Salt Lake City, UT, USA.
J WagstaffSingleton Hospital, South West Wales Cancer Institute & Swansea University College of Medicine, Swansea, United Kingdom.
J ChesneyUniversity of Louisville, Louisville, KY, USA.
M O ButlerPrincess Margaret Cancer Centre, Department of Medical Oncology, Department of Immunology, University of Toronto, Toronto, ON, Canada.
O BechterLeuven Cancer Institute, University Hospitals Leuven, Belgium.
I Márquez-RodasGeneral University Hospital Gregorio Marañón, Madrid, Spain.
A C PavlickMeyer Cancer Center, Weill Cornell Medical College, New York, NY, USA.
P DuraniBristol Myers Squibb, Princeton, NJ, USA.
M Pe BenitoBristol Myers Squibb, Princeton, NJ, USA.
P WangBristol Myers Squibb, Princeton, NJ, USA.
M A PostowMeyer Cancer Center, Weill Cornell Medical College, New York, NY, USA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
P A AsciertoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeTo investigate the predictive value of RECIST response within 3, 6, or 12 months on long-term survival, and explore differences between nivolumab+ipilimumab and nivolumab monotherapy, we analyzed pooled 5-year data of 935 responder and non-responder patients at various time points after treatment initiation in CheckMate 069, 066, and 067 studies. PATIENTS AND

methodsTreatment-naive advanced melanoma patients received nivolumab+ipilimumab or nivolumab monotherapy. To decrease immortal time bias, 3-, 6-, or 12-month overall survival (OS) and progression-free survival (PFS) landmark analyses were performed. Association between characteristics and response was evaluated by univariate and multivariate analyses.

resultsResponse rates at any time were 58 % (239/409) for nivolumab+ipilimumab and 44 % (230/526) for nivolumab monotherapy. In 12-month landmark analyses, 5-year OS rates for responders versus non-responders were 82 % versus 40 % with nivolumab+ipilimumab (HR=0.23 [95 % CI, 0.15-0.35]) and 76 % versus 32 % with nivolumab monotherapy (HR=0.22 [95 % CI, 0.16-0.31]). PFS rates were 83 % versus 32 % and 69 % versus 46 %, respectively. Similar strong associations between response at 3 and 6 months and 5-year OS and PFS were also observed with more than 70 % of the responses observed in the first 3 months. Response rates correlated with baseline LDH and PD-L1 status by multivariate analysis but the association between response and long-term survival was maintained in landmark analyses even among patients with high LDH and low PD-L1 expression.

conclusionClinical response evaluated in the first months of therapy is a strong predictor of long-term survival, even in patients with poor prognostic biomarkers.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsIpilimumabMelanomaNivolumabAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProgression-Free SurvivalSkin NeoplasmsTime FactorsTreatment OutcomeIpilimumabNivolumabAdvanced melanomaClinical responseIpilimumabLong-term survivalNivolumabPrognostic factors

Identifiers

PMID39612757
PMCPMC13479941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.